Vladimir Vexler
Plus aucun poste en cours
Fortune : 182 505 $ au 31/03/2024
Profil
Vladimir Vexler worked as a Director of Translational Medicine at Abbott Biotherapeutics Corp.
and PDL BioPharma, Inc. before becoming a Fellow at The University of California, San Francisco.
He then served as the EVP of Analytical & Translational Sciences at Coherus BioSciences, Inc. Dr. Vexler holds a graduate degree from Moscow State University Lomonosov and a doctorate from the Russian Academy of Sciences.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 10/04/2023 | 76 362 ( 0,07% ) | 182 505 $ | 31/03/2024 |
Anciens postes connus de Vladimir Vexler
| Sociétés | Poste | Fin |
|---|---|---|
| COHERUS BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 10/03/2023 |
| The University of California, San Francisco | Corporate Officer/Principal | - |
| PDL BIOPHARMA, INC. | Corporate Officer/Principal | - |
Abbott Biotherapeutics Corp.
 Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Corporate Officer/Principal | - |
Formation de Vladimir Vexler
| Moscow State University Lomonosov | Graduate Degree |
| Russian Academy of Sciences | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| COHERUS BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Health Technology |
PDL BioPharma, Inc.
 PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
